Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report

OBJECTIVE: Previous studies have shown that fusion partners have a potential role in influencing different tumorigenic abilities of ROS1 fusion variants, as well as potential differential responses to crizotinib. Therefore, it is important to accurately identify the type of ROS1 rearrangement in NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, YunYu, Lei, Yan, Li, LinWei, Su, Xiaoxing, Tian, Qiqi, Wu, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342878/
https://www.ncbi.nlm.nih.gov/pubmed/35923471
http://dx.doi.org/10.2147/OTT.S372134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342878/
https://www.ncbi.nlm.nih.gov/pubmed/35923471
http://dx.doi.org/10.2147/OTT.S372134

Ejemplares similares